Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 76

Sort by

Sort Order Select

Journal Articles

Mitophagy As a Novel Cell-Protective Mechanism Against Mitochondrial Ferroptosis in Acute Myeloid Leukemia

Hiroki Akiyama, Matthew Tcheng, Priyanka Sharma, Ran Zhao, Lauren B. Ostermann, Samar Yazdani, Arman Moayed, Zdzislaw Szulc, Natalia Oleinik, Po Yee Mak, Vivian Ruvolo, Bing Z. Carter, Besim Ogretmen, Gautam Borthakur, Aaron D. Schimmer, Michael Andreeff, Jo Ishizawa

Blood (2023) 142 (Supplement 1): 2804.

https://doi.org/10.1182/blood-2023-181410

Published: 2023

Journal Articles

ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Altering Drp1-Dependent Mitochondrial Fission and Metabolism

Priyanka Sharma, Sujan Piya, Natalia Baran, Anna Zal, Christopher J. Hindley, Kim-Hien Dao, Martin Sims, Tomasz Zal, Vivian Ruvolo, Michael Andreeff, Gautam Borthakur

Blood (2022) 140 (Supplement 1): 8789–8790.

https://doi.org/10.1182/blood-2022-167171

Published: 2022

Journal Articles

Targeting Vimentin (VIM) in Acute Myelogenous Leukemia (AML)

Stefan Hubner, Marina Konopleva, Zhihong Zeng, Fieke W Hoff, Yihua Qiu, Vivian Ruvolo, Terzah M. Horton, Steven M. Kornblau

Blood (2022) 140 (Supplement 1): 6260–6261.

https://doi.org/10.1182/blood-2022-163664

Published: 2022

Journal Articles

Inhibition of ERK1/2 Reverses Venetoclax-Induced Autophagy to Overcome Resistance in Acute Myeloid Leukemia

Priyanka Sharma, Sujan Piya, Natalia Baran, Muharrem Muftuoglu, Mahesh Basyal, Vivian Ruvolo, Christopher J. Hindley, Kim-Hien Dao, Martin Sims, Michael Andreeff, Gautam Borthakur

Blood (2022) 140 (Supplement 1): 3093–3094.

https://doi.org/10.1182/blood-2022-165552

Published: 2022

Journal Articles

C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53 -Independent Cell Death in Acute Myeloid Leukemia and Lymphomas

Yuki Nishida, Darah A Scruggs, Edward Ayoub, Tallie Patsilevas, Vivian Ruvolo, Po Yee Mak, Bing Z Carter, Steffen Boettcher, Abhishek Maiti, Qianxiang Zhou, Zhaohui Yang, Honghua Yan, Liandong Ma, Michael Andreeff

Blood (2022) 140 (Supplement 1): 483–484.

https://doi.org/10.1182/blood-2022-164968

Published: 2022

Journal Articles

Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML

Yuki Nishida, Jo Ishizawa, Edward Ayoub, Tallie Patsilevas, Lauren Ostermann, Rafael Heinz Montoya, Muharrem Muftuoglu, Vivian Ruvolo, Po Yee Mak, Wenjing Tao, Bing Z Carter, Kensuke Kojima, Naval Daver, Arnaud Lesegretain, Takahiko Seki, Sharon Shacham, Marina Konopleva, Michael Andreeff

Blood (2021) 138 (Supplement 1): 505.

https://doi.org/10.1182/blood-2021-149260

Published: 2021

Journal Articles

Inhibition of De Novo Pyrimidine Synthesis Depletes Acute Myleogenous Leukemia Stem Cells (LSCs) Burden and Triggers Apoptosis and Differentiation Associated with Oxidative Stress

Sujan Piya, Huaxian Ma, Priyanka Sharma, Kensuke Kojima, Vivian Ruvolo, Mahesh Basyal, Natalia Baran, Marla Weetall, Josephine Sheedy, Balmiki Ray, Michael Andreeff, Gautam Borthakur

Blood (2021) 138 (Supplement 1): 2249.

https://doi.org/10.1182/blood-2021-148136

Published: 2021

Journal Articles

Combination Therapy of FLT3 Tyrosine Kinase Inhibitors and BH3 Mimetics Targeting Antiapoptotic MCL-1 Synergistically Eliminates FLT3-ITD Acute Myeloid Leukemia Cells in Vitro and In Vivo

Blood (2021) 138 (Supplement 1): 2248.

https://doi.org/10.1182/blood-2021-151042

Published: 2021

Journal Articles

Combined Inhibition of Bcl-2 and Mcl-1 Circumvents Resistance of TP53 Deficient/Mutant AML to BH3 Mimetics

Bing Z Carter, Po Yee Mak, Wenjing Tao, Lauren B Ostermann, Steffen Boettcher, Yuki Nishida, Edward Ayoub, Vivian Ruvolo, Elias J. Jabbour, Paul Hughes, PK Morrow, Michael Andreeff

Blood (2021) 138 (Supplement 1): 2239.

https://doi.org/10.1182/blood-2021-148014

Published: 2021

Journal Articles

Inhibition of Cyclin Dependent Kinase 8(CDK8): A Novel Approach to Target the Leukemia Initiating Cells (LICs) in T-Cell Acute Lymphoblastic Leukaemia (T-ALL)

Sujan Piya, Huaxian Ma, Sujan Piya, Vivian Ruvolo, Mahesh Basyal, Aniela Golas, Renata Windak, Tomasz Rzymski, Michael Andreeff, Gautam Borthakur

Blood (2021) 138 (Supplement 1): 2250.

https://doi.org/10.1182/blood-2021-148853

Published: 2021

Journal Articles

ERK1/2 Inhibition Overcomes Resistance in Acute Myeloid Leukemia (AML) and Alters Mitochondrial Dynamics

Priyanka Sharma, Sujan Piya, Huaxian Ma, Natalia Baran, Malgorzata Anna Zal, Christopher J. Hindley, Kim-Hien Dao, Martin Sims, Tomasz Zal, Vivian Ruvolo, Michael Andreeff, Gautam Borthakur

Blood (2021) 138 (Supplement 1): 3338.

https://doi.org/10.1182/blood-2021-151579

Published: 2021

Journal Articles

Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance

Blood (2021) 138 (Supplement 1): 370.

https://doi.org/10.1182/blood-2021-153426

Published: 2021

Journal Articles

Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML

Bing Z Carter, PhD, Po Yee Mak, Vivian Ruvolo, MS, Wenjing Tao, Paul Hughes, Xiaoyue Chen, PK Morrow, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-141399

Published: 2020

Journal Articles

BCL2A1 : A Novel Target in Refractory Acute Myeloid Leukemia with FLT3 -ITD/D835 Dual Mutations

Kotoko Yamatani, MD, Tomohiko Ai, MDPhD, Kaori Saito, Haeun Yang, Vivian Ruvolo, MS, Po Yee Mak, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Hironori Harada, MD PhD, Kazuhiro Katayama, PhD, Takashi Miida, MD PhD, Marina Konopleva, MD PhD, Weiguo Zhang, MD PhD, Bing Z Carter, PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD, Yoko Tabe, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136587

Published: 2020

Journal Articles

High Dimensional Interrogation of Stress Response Patterns and Cell Death Modes in AML

Muharrem Muftuoglu, MD, Po Yee Mak, Vivian Ruvolo, MS, Yuki Nishida, MDPhD, Peter P. Ruvolo, PhD, Bing Z Carter, PhD, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-143371

Published: 2020

Journal Articles

Exportin-1 (XPO1) Inhibition Sequesters p53 from MDM2 and MDM4 and Is Highly Synergistic with MDM2 Inhibition in Inducing Apoptosis in Wild-Type p53 Acute Myeloid Leukemias

Yuki Nishida, MDPhD, Jo Ishizawa, MDPhD, Edward Ayoub, PhD MS, BSc, Rafael Heinz Montoya, BS, Vivian Ruvolo, MS, Kensuke Kojima, MD PhD, Naval Daver, MD, Arnaud Lesegretain, Sharon Shacham, PhD MBA, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-140768

Published: 2020

Journal Articles

Co-Targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-Resistant and TP53 Mutated AML

Bing Z Carter, PhD, Po Yee Mak, Wenjing Tao, Vivian Ruvolo, MS, Xuan Zhang, PhD, Yuki Nishida, MD PhD, Steven M. Kornblau, MD, Paul Hughes, Xiaoyue Chen, PK Morrow, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 7.

https://doi.org/10.1182/blood-2020-141417

Published: 2020

Journal Articles

The Novel Dihydroorotate Dehydrogenase (DHODH) Inhibitor PTC299 Inhibit De Novo Pyrimidine Synthesis with Broad Anti-Leukemic Activity Against Acute Myeloid Leukemia

Sujan Piya, PhD, Marla Weetall, PhD, Josephine Sheedy, BS, MSc, Balmiki Ray, PhD, Huaxian Ma, MS, Kensuke Kojima, MD PhD, Vivian Ruvolo, MS, Mahesh Basyal, BS, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD, Gautam Borthakur, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-139940

Published: 2020

Journal Articles

The Direct Interactions with Bone Marrow Microenvironment Confer Resistance to the Inhibition of Oxidative Phosphorylation in AML

Yoko Tabe, MD PhD, Kaori Saito, Kotoko Yamatani, MD, Haeun Yang, Rodrigo Jacamo, PhD, Helen Ma, MS, Vivian Ruvolo, MS, Qi Zhang, PhD, Vinitha Mary Kuruvilla, MSc, Natalia Baran, PhDMD, Junichi Imoto, Kazuho Ikeo, PhD, Koya Suzuki, PhD, Takashi Miida, MD PhD, Michael Andreeff, MD PhD, Christopher P Vellano, Joseph R Marszalek, PhD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-137366

Published: 2020

Journal Articles

Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3 -ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-142687

Published: 2020

NARROW

Mitophagy As a Novel Cell-Protective Mechanism Against Mitochondrial Ferroptosis in Acute Myeloid Leukemia

ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Altering Drp1-Dependent Mitochondrial Fission and Metabolism

Targeting Vimentin (VIM) in Acute Myelogenous Leukemia (AML)

Inhibition of ERK1/2 Reverses Venetoclax-Induced Autophagy to Overcome Resistance in Acute Myeloid Leukemia

C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53 -Independent Cell Death in Acute Myeloid Leukemia and Lymphomas

Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML

Inhibition of De Novo Pyrimidine Synthesis Depletes Acute Myleogenous Leukemia Stem Cells (LSCs) Burden and Triggers Apoptosis and Differentiation Associated with Oxidative Stress

Combination Therapy of FLT3 Tyrosine Kinase Inhibitors and BH3 Mimetics Targeting Antiapoptotic MCL-1 Synergistically Eliminates FLT3-ITD Acute Myeloid Leukemia Cells in Vitro and In Vivo

Combined Inhibition of Bcl-2 and Mcl-1 Circumvents Resistance of TP53 Deficient/Mutant AML to BH3 Mimetics

Inhibition of Cyclin Dependent Kinase 8(CDK8): A Novel Approach to Target the Leukemia Initiating Cells (LICs) in T-Cell Acute Lymphoblastic Leukaemia (T-ALL)

ERK1/2 Inhibition Overcomes Resistance in Acute Myeloid Leukemia (AML) and Alters Mitochondrial Dynamics

Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance

Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML

BCL2A1 : A Novel Target in Refractory Acute Myeloid Leukemia with FLT3 -ITD/D835 Dual Mutations

High Dimensional Interrogation of Stress Response Patterns and Cell Death Modes in AML

Exportin-1 (XPO1) Inhibition Sequesters p53 from MDM2 and MDM4 and Is Highly Synergistic with MDM2 Inhibition in Inducing Apoptosis in Wild-Type p53 Acute Myeloid Leukemias

Co-Targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-Resistant and TP53 Mutated AML

The Novel Dihydroorotate Dehydrogenase (DHODH) Inhibitor PTC299 Inhibit De Novo Pyrimidine Synthesis with Broad Anti-Leukemic Activity Against Acute Myeloid Leukemia

The Direct Interactions with Bone Marrow Microenvironment Confer Resistance to the Inhibition of Oxidative Phosphorylation in AML

Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3 -ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only